DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.

Autores: Lee, H.C.; Cohen, A.D.; Chari, A.; Hultcrantz, M.; Nooka, A.K.; Callander, N.S.; Suvannasankha, A.; Badros, A.; Libby, E.N.; Trudel, S.; Richardson, P.G.; Sborov, D.W.; Rodríguez Otero, Paula; Lonial, S.; Zhi, E.; Lewis, E.; Gupta, I.; Opalinska, J.